This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Is Endothelial Function a Predictor of Successful Ablation Therapy Provided to Patients With Atrial Fibrillation?

This study has been completed.
Information provided by (Responsible Party):
Itamar-Medical, Israel Identifier:
First received: April 30, 2014
Last updated: March 8, 2017
Last verified: December 2014
The purpose of this study is to assess whether normal endothelial function in patients with Atrial Fibrillation undergoing ablation procedure increases the chances of a favorable clinical outcome and maintaining sinus rhythm following ablation

Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Non-randomized, Double Blind Multicenter Study to Assess Endothelial Function Using Endo-PAT2000 and Its Correlation to Clinical Outcome Following Ablation in Patients With Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by Itamar-Medical, Israel:

Primary Outcome Measures:
  • Freedom from AF/AFL/AT off antiarrhythmic drugs therapy [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Acute procedural success: Pulmonary veins isolation [ Time Frame: 12 months ]
  • 75% reduction in the number/duration of AFib episodes [ Time Frame: 12 months ]

Estimated Enrollment: 150
Study Start Date: May 2014
Study Completion Date: November 2016
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Atrial Fibrillation

Detailed Description:

In the recent years, increasing evidence is linking inflammation to AFib. In addition, it has been shown that ablation improves endothelial function, suggesting that AFib might be associated with the etiology of endothelial dysfunction.

The objective of this study is to assess endothelial function using Endo-PAT2000 and its correlation to clinical outcome following ablation of patients with Atrial Fibrillation (AFib).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
AFib patients eligible for ablation treatment

Inclusion Criteria:

  • All patients with AF considered eligible for ablation treatment may be included in this study (following unsuccessful attempts with AAD).
  • Patients on optimal anticoagulation therapy
  • The minimum AF documentation required as defined by the Heart Rhythm Society

Exclusion Criteria:

  • Patients age below 18 years
  • Cases with extremely abnormal anatomy (i.e., inverted heart)
  • Moderate or severe mitral valve disease or mitral prosthetic valve
  • Ejection fraction less than 30%
  • Left atrial anteroposterior diameter more than 50 mm evaluated by echo or CT data (up to 6 months old)..
  • Previous atrial fibrillation ablation occurred less than 6 months prior
  • Left atrium thrombus
  • Acute infective disease or sepsis in the last 3 months
  • Acute myocardial infarction in last 3 months
  • Reduced expectancy of life (less than 12 months)
  • Patient participating in another clinical study that investigates a drug or device unless prior approval is given by the sponsor
  • Psychologically unstable patient or denies to give informed consent
  • Deformities of the digits of the upper extremities, which preclude adequate signal acquisition
  • Patients under the effect of short-acting Nitroglycerin (3 hours washout period)
  • Patient suffering from a medical condition prohibiting blood flow occlusion in both arms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02129842

United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
New York University School of Medicine
NY, New York, United States, 10016
United States, Texas
Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, United States, 78075
University Heart Center Hamburg
Hamburg, Germany, 20246
Sheba Medical Center
Ramat Gan, Israel, 52621
United Kingdom
Royal Brompton & Harefield NHS Foundation Trust
London, United Kingdom
Sponsors and Collaborators
Itamar-Medical, Israel
  More Information

Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012 Apr;14(4):528-606. doi: 10.1093/europace/eus027. Epub 2012 Mar 1.

Responsible Party: Itamar-Medical, Israel Identifier: NCT02129842     History of Changes
Other Study ID Numbers: Endo-AFib-001
Study First Received: April 30, 2014
Last Updated: March 8, 2017

Keywords provided by Itamar-Medical, Israel:
Endothelial dysfunction

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on August 18, 2017